Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $7.50.
Several research analysts have issued reports on ACET shares. Wall Street Zen started coverage on Adicet Bio in a research report on Friday, May 16th. They set a "hold" rating for the company. Guggenheim restated a "buy" rating and set a $7.00 target price on shares of Adicet Bio in a research report on Friday, March 21st.
Read Our Latest Analysis on ACET
Adicet Bio Stock Up 4.4%
NASDAQ ACET traded up $0.03 during trading hours on Friday, hitting $0.71. 393,082 shares of the company were exchanged, compared to its average volume of 645,111. The stock has a 50-day moving average price of $0.68 and a 200 day moving average price of $0.77. Adicet Bio has a 52 week low of $0.45 and a 52 week high of $1.70. The stock has a market cap of $58.97 million, a PE ratio of -0.55 and a beta of 1.62.
Adicet Bio (NASDAQ:ACET - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.03. As a group, sell-side analysts anticipate that Adicet Bio will post -1.39 earnings per share for the current year.
Institutional Trading of Adicet Bio
A number of large investors have recently modified their holdings of ACET. Regeneron Pharmaceuticals Inc. purchased a new stake in shares of Adicet Bio in the fourth quarter valued at approximately $931,000. Norges Bank purchased a new stake in shares of Adicet Bio in the fourth quarter valued at approximately $413,000. Squarepoint Ops LLC purchased a new stake in shares of Adicet Bio in the fourth quarter valued at approximately $177,000. Bridgeway Capital Management LLC boosted its holdings in shares of Adicet Bio by 20.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 1,026,600 shares of the company's stock valued at $988,000 after purchasing an additional 175,000 shares during the period. Finally, Wealthedge Investment Advisors LLC boosted its holdings in shares of Adicet Bio by 208.8% in the first quarter. Wealthedge Investment Advisors LLC now owns 227,801 shares of the company's stock valued at $172,000 after purchasing an additional 154,037 shares during the period. Hedge funds and other institutional investors own 83.89% of the company's stock.
About Adicet Bio
(
Get Free ReportAdicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Featured Articles

Before you consider Adicet Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adicet Bio wasn't on the list.
While Adicet Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.